Myriad Genetics Inc (MYGN): Cost of Revenue

Annual figures by period end, from SEC filings.

$247.90M

Year ended 2025-12-31

$251.40M

Trailing 12 months to 2026-06-30

+7.1%

3-year compound annual growth

2022-12-31 Cost of Revenue (USD) 2025-12-31

Period ended	Cost of Revenue	Change YoY	Source filing
2025-12-31	$247.90M	-1.7%	2026-02-24, From 2025-01-01
2024-12-31	$252.20M	+6.8%	2026-02-24, From 2024-01-01
2023-12-31	$236.20M	+16.9%	2026-02-24, From 2023-01-01
2022-12-31	$202.00M	n/a	2025-02-28, From 2022-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Cost of Revenue	Change YoY
Myriad Genetics Inc (MYGN)	2025-12-31	$247.90M	-1.7%
Neogen Corp (NEOG)	2026-05-31	$461.90M	-2.4%
Lantheus Holdings, Inc. (LNTH)	2025-12-31	$599.66M	+9.9%
Idexx Laboratories Inc (IDXX)	2025-12-31	$1.64B	+8.3%
Alpha Teknova, Inc. (TKNO)	2025-12-31	$27.08M	-11.3%
Immucell Corp (ICCC)	2025-12-31	$16.20M	-12.7%
Aspira Women's Health Inc. (AWHL)	2025-12-31	$3.30M	-10.9%
Anbio Biotechnology (NNNN)	2025-12-31	$1.10M	-52.0%
Biomerica Inc (BMRA)	2026-05-31	$4.09M	-15.0%

Compare MYGN, NEOG, LNTH, IDXX side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗